Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Oct 31, 2025 | (Q2)Jul 31, 2025 | (Q1)Apr 30, 2025 | (FY)Jan 31, 2025 | (Q4)Jan 31, 2025 | (Q3)Oct 31, 2024 | (Q2)Jul 31, 2024 | (Q1)Apr 30, 2024 | (FY)Jan 31, 2024 | (Q4)Jan 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -110.89%-486.44K | -0.04%-459.55K | 51.39%-396.96K | 1.09%-1.65M | 77.10%-147.45K | 43.13%-230.66K | -105.13%-459.36K | -104.70%-816.59K | -158.96%-1.67M | -167.17%-643.88K |
| Net income from continuing operations | -315.58%-402.85K | -63.74%-251.47K | 65.36%-345.86K | -101.59%-2.14M | -55.02%-894.66K | 26.08%-96.94K | -66.51%-153.58K | -279.89%-998.4K | -35.72%-1.06M | -52.81%-577.13K |
| Depreciation and amortization | --0 | ---- | ---- | ---- | ---- | --9.03K | --9.03K | --9.03K | ---- | ---- |
| Asset impairment expenditure | ---- | ---- | --0 | 116.08%419K | ---- | ---- | ---- | --9.03K | --193.91K | ---- |
| Remuneration paid in stock | --0 | --0 | --0 | 1,806.17%618K | --144K | --0 | --0 | 1,799.95%474K | -87.53%32.42K | --0 |
| Other non cashItems | 84.52%-49.23K | 75.12%-59.53K | -45.56%-67.4K | -26.33%-764.41K | 10.50%-160.76K | -12.34%-318.04K | -91.73%-239.3K | -164.03%-46.3K | -760.48%-605.07K | -353.00%-179.62K |
| Change In working capital | -119.61%-34.37K | -96.72%-148.55K | 106.39%16.29K | 194.19%216.91K | 559.07%372.06K | 1,932.27%175.28K | -425.75%-75.51K | -77.62%-254.92K | -343.42%-230.3K | -5.84%-81.05K |
| -Change in receivables | -300.29%-220.67K | 46.33%-36.97K | -67.73%66.45K | 182.88%249.92K | 101.33%2.7K | 4,437.72%110.18K | -50.23%-68.89K | 512.19%205.93K | -318.19%-301.54K | -75.94%-203.18K |
| -Change in payables and accrued expense | 186.16%186.31K | -1,584.69%-111.58K | 89.12%-50.16K | -146.34%-33.01K | 202.42%369.36K | 483.12%65.11K | -121.03%-6.62K | -392.59%-460.85K | 253.21%71.24K | 213.93%122.14K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -110.89%-486.44K | -0.04%-459.55K | 51.39%-396.96K | 1.09%-1.65M | 77.10%-147.45K | 43.13%-230.66K | -105.13%-459.36K | -104.70%-816.59K | -158.96%-1.67M | -167.17%-643.88K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 81.38%-297.85K | 4.45%-238.16K | -45.29%-189.79K | -35.31%-3.69M | -21.13%-1.71M | -98.01%-1.6M | 41.91%-249.26K | -67.86%-130.62K | -296.49%-2.73M | -125.52%-1.41M |
| Capital expenditure reported | ---- | ---- | ---- | -0.11%-500.56K | ---- | ---- | ---- | ---- | 3.75%-500K | ---- |
| Net PPE purchase and sale | ---- | ---- | ---- | -0.11%-500.56K | ---500.56K | ---- | ---- | ---- | 3.75%-500K | ---- |
| Net investment purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Interest received (cash flow from investment activities) | ---- | ---- | ---- | -3.35%-1.11K | ---- | ---- | ---- | ---- | ---1.08K | ---- |
| Net other investing changes | 82.02%-287.6K | 4.45%-238.16K | -45.29%-189.79K | -43.23%-3.19M | -32.66%-1.21M | -98.01%-1.6M | 41.91%-249.26K | -67.86%-130.62K | -1,450.90%-2.23M | -1,009.09%-912.31K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 81.38%-297.85K | 4.45%-238.16K | -45.29%-189.79K | -35.31%-3.69M | -21.13%-1.71M | -98.01%-1.6M | 41.91%-249.26K | -67.86%-130.62K | -296.49%-2.73M | -125.52%-1.41M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 138,109.78%10.47M | -58.95%318.7K | -24.42%1.68M | 13.95%3.82M | -67.51%828.08K | 30.62%-7.59K | -4.53%776.28K | 2.22M | 8.36%3.35M | -17.59%2.55M |
| Net issuance payments of debt | 15.79%-7.86K | 15.46%-7.73K | -11.97%-10.04K | -20.46%-36.96K | 68.98%-9.52K | ---9.33K | ---9.15K | ---8.97K | ---30.69K | ---30.69K |
| Net common stock issuance | --11.09M | -100.00%-1 | -23.83%1.73M | 11.39%3.95M | -66.95%899.25K | --0 | -5.13%785.87K | --2.27M | 10.07%3.55M | -15.62%2.72M |
| Proceeds from stock option exercised by employees | --146.23K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | --0 | ---- |
| Net other financing activities | -43,675.96%-759.53K | -208.14%-1.36K | -2.22%-38.67K | 41.41%-98.19K | 56.39%-61.66K | 115.94%1.74K | ---442 | ---37.83K | 13.92%-167.58K | 27.19%-141.38K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 138,109.78%10.47M | -58.95%318.7K | -24.42%1.68M | 13.95%3.82M | -67.51%828.08K | 30.62%-7.59K | -4.53%776.28K | --2.22M | 8.36%3.35M | -17.59%2.55M |
| Net cash flow | ||||||||||
| Beginning cash position | -69.15%961.66K | -56.04%1.34M | -86.01%248.31K | -37.15%1.78M | -0.31%1.28M | 24.30%3.12M | 29.90%3.05M | -37.15%1.78M | 164.98%2.82M | 114.19%1.28M |
| Current changes in cash | 627.17%9.69M | -660.10%-379.01K | -14.29%1.09M | -45.51%-1.53M | -309.79%-1.03M | -50.10%-1.84M | -57.74%67.67K | 367.34%1.27M | -159.67%-1.05M | -77.91%491.61K |
| End cash Position | 732.22%10.65M | -69.15%961.66K | -56.04%1.34M | -86.01%248.31K | -86.01%248.31K | -0.31%1.28M | 24.30%3.12M | 29.90%3.05M | -37.15%1.78M | -37.15%1.78M |
| Free cash from | -115.33%-496.69K | -0.04%-459.55K | 51.39%-396.96K | 0.82%-2.15M | 43.35%-648.01K | 43.13%-230.66K | -105.13%-459.36K | -104.70%-816.59K | -86.43%-2.17M | -50.42%-1.14M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.